289 related articles for article (PubMed ID: 24164171)
1. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
Norrby K
APMIS; 2014 Jul; 122(7):565-79. PubMed ID: 24164171
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
[TBL] [Abstract][Full Text] [Related]
3. Metronomic therapy: chemotherapy revisited.
Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
[TBL] [Abstract][Full Text] [Related]
4. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
5. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
6. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
7. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
8. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Ciccolini J; Barbolosi D; Meille C; Lombard A; Serdjebi C; Giacometti S; Padovani L; Pasquier E; André N
Cancer Res; 2017 Sep; 77(17):4723-4733. PubMed ID: 28655786
[TBL] [Abstract][Full Text] [Related]
10. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
Albertsson P; Lennernäs B; Norrby K
Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
[TBL] [Abstract][Full Text] [Related]
11. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
Hida K; Kikuchi H; Maishi N; Hida Y
Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
[TBL] [Abstract][Full Text] [Related]
13. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
14. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
15. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Murray A; Little SJ; Stanley P; Maraveyas A; Cawkwell L
Oncol Rep; 2010 Oct; 24(4):1049-58. PubMed ID: 20811688
[TBL] [Abstract][Full Text] [Related]
17. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
Naganuma Y; Choijamts B; Shirota K; Nakajima K; Ogata S; Miyamoto S; Kawarabayashi T; Emoto M
Cancer Sci; 2011 Aug; 102(8):1545-52. PubMed ID: 21631643
[TBL] [Abstract][Full Text] [Related]
18. Resistance to metronomic chemotherapy and ways to overcome it.
Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U
Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819
[TBL] [Abstract][Full Text] [Related]
19. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
20. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
